Sector: Healthcare | Industry: Managed Health Care |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Waterview Plaza Suite 310, 2001 Route 46 PARSIPPANY NJ 07054 |
Tel: | N/A |
Website: | https://www.interpace.com |
IR: | See website |
Key People | ||
Thomas W. Burnell President, Chief Executive Officer, Director | Christopher Mccarthy Chief Financial Officer |
Business Overview |
Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin. |
Financial Overview |
For the fiscal year ended 31 December 2023, Interpace Biosciences Inc revenues increased 26% to $40.2M. Net income before extraordinary items totaled $1.1M vs. loss of $5.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Selling/General/Admin. Exp decrease of 15% to $9.4M (expense), Other expense, net decrease of 45% to $667K (expense). |
Employees: | 108 as of Feb 29, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $58.81M as of Dec 31, 2023 |
Annual revenue (TTM): | $40.21M as of Dec 31, 2023 |
EBITDA (TTM): | $3.83M as of Dec 31, 2023 |
Net annual income (TTM): | $1.11M as of Dec 31, 2023 |
Free cash flow (TTM): | $3.32M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $5.85M as of Dec 31, 2023 |
Shares outstanding: | 4,376,398 as of Mar 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |